Table 1.
Comparative MOST-1 expression in human tissues, normal cell lines, and cancer cell lines
| Normal tissues | MOST-1: G3PDH ratio | Cell lines | MOST-1: G3PDH ratio |
| Pancreas | 0.61 | MRC-5 fetal lung cells | 1.35 |
| Prostate | 0.57 | Breast myoepithelial cells | 1.15 |
| Ovary | 0.55 | MDA-MB-231 breast adenocarcinoma | 2.11 |
| Testis | 0.33 | Hs578T breast ductal carcinoma | 1.14 |
| Liver | 0.33 | MCF7 breast adenocarcinoma | 1.13 |
| Heart | 0.31 | ZR-75-1 breast ductal carcinoma | 0.44 |
| Kidney | 0.31 | PC-3 prostate adenocarinoma | 1.20 |
| Thymus | 0.28 | DU145 prostate carcinoma | 1.13 |
| Small intestine | 0.26 | CaSki cervical carcinoma | 1.18 |
| Lung* | 0.17 | HeLa cervical carcinoma | 1.06 |
| Peripheral leucocytes* | 0.17 | SiHa cervical carcinoma | 0.90 |
| Skeletal muscle* | 0.14 | T24 bladder carcinoma | 0.86 |
| Placenta* | 0.08 | HepG2 hepatocellular carcinoma | 1.08 |
| Colon* | 0.06 | Hep3B hepatocellular carcinoma | 0.95 |
| Brain* | 0.02 | PLC/PRF/5 hepatocellular carcinoma | 0.69 |
| Spleen* | 0.00 | Mahlavu hepatocellular carcinoma | 0.64 |
| KATO III gastric carcinoma | 0.76 | ||
| U-937 histiocytic lymphoma | 1.59 | ||
| Raji Burkitt’s lymphoma | 0.96 | ||
| HL-60 promyelocytic leukaemia | 0.95 | ||
| MOLT-4 T-lymphoblastic leukaemia | 0.94 |
All cDNA samples were subjected to PCR with MOST-1 and G3PDH primers, and the individual ratios of the densitometric readings of their amplified products were calculated. *Samples for which no MOST-1 amplified products were visualised by agarose gel electrophoresis.
G3PDH, glyceraldehyde-3-phosphate dehydrogenase; PCR, polymerase chain reaction.